Abstract
The chemotactic factor inactivator (CFI) in human serum appears to have important regulatory function in the inflammatory response. In humans with elevated serum levels of CFI, defective mobilization of leukocytes in vivo has been noted, both in skin windows and in skin testing with various antigens. In experimental immune complex-induced acute inflammatory reactions in rat skin and lung, purified human CFI at very low doses has potent antiinflammatory effects and is able to suppress permeability changes, neutrophil infiltration, and hemorrhage, all of which are dependent initially on the role of leukotactic mediators.
Full text
PDF
Images in this article
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Alper C. A., Rosen F. S. Genetic aspects of the complement system. Adv Immunol. 1971;14:251–290. doi: 10.1016/s0065-2776(08)60286-2. [DOI] [PubMed] [Google Scholar]
- Berenberg J. L., Ward P. A. Chemotactic factor inactivator in normal human serum. J Clin Invest. 1973 May;52(5):1200–1206. doi: 10.1172/JCI107287. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Bokisch V. A., Müller-Eberhard H. J. Anaphylatoxin inactivator of human plasma: its isolation and characterization as a carboxypeptidase. J Clin Invest. 1970 Dec;49(12):2427–2436. doi: 10.1172/JCI106462. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Brozna J. P., Ward P. A. Antileukotactic properties of tumor cells. J Clin Invest. 1975 Sep;56(3):616–623. doi: 10.1172/JCI108131. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Bullock W. E., Jr, Ho M. F., Chen M. J. Quantitative and qualitative studies of the local cellular exudative response in leprosy. J Reticuloendothel Soc. 1974 Nov;16(5):259–268. [PubMed] [Google Scholar]
- Johnson K. J., Anderson T. P., Ward P. A. Suppression of immune complex-induced inflammation by the chemotactic factor inactivator. J Clin Invest. 1977 May;59(5):951–958. doi: 10.1172/JCI108717. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Johnson K. J., Ward P. A. Acute immunologic pulmonary alveolitis. J Clin Invest. 1974 Aug;54(2):349–357. doi: 10.1172/JCI107770. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Maderazo E. C., Ward P. A., Quintiliani R. Defective regulation of chemotaxis in cirrhosis. J Lab Clin Med. 1975 Apr;85(4):621–630. [PubMed] [Google Scholar]
- Maderazo E. G., Ward P. A., Woronick C. L., Kubik J., DeGraff A. C., Jr Leukotactic dystunction in sarcoidosis. Ann Intern Med. 1976 Apr;84(4):414–419. doi: 10.7326/0003-4819-84-4-414. [DOI] [PubMed] [Google Scholar]
- Till G., Ward P. A. Two distinct chemotactic factor inactivators in human serum. J Immunol. 1975 Feb;114(2 Pt 2):843–847. [PubMed] [Google Scholar]
- Ward P. A., Berenberg J. L. Defective regulation of inflammatory mediators in Hodgkin's disease. Supernormal levels of chemotactic-factor inactivator. N Engl J Med. 1974 Jan 10;290(2):76–80. doi: 10.1056/NEJM197401102900203. [DOI] [PubMed] [Google Scholar]
- Ward P. A., Goralnick S., Bullock W. E. Defective leukotaxis in patients with lepromatous leprosy. J Lab Clin Med. 1976 Jun;87(6):1025–1032. [PubMed] [Google Scholar]
- Ward P. A., Hill J. H. Biologic role of complement products. Complement-derived leukotactic activity extractable from lesions of immunologic vasculitis. J Immunol. 1972 May;108(5):1137–1145. [PubMed] [Google Scholar]
- Ward P. A., Ozols J. Characterization of the protease activity in the chemotactic factor inactivator. J Clin Invest. 1976 Jul;58(1):123–129. doi: 10.1172/JCI108440. [DOI] [PMC free article] [PubMed] [Google Scholar]